touchCONGRESS Expert Interviews: Continuing the conversation in paediatric endocrinology – how do the latest advances in understanding biology translate to improved patient care?

Introduction

Watch a series of renowned European paediatric endocrinology specialists discuss key data about paediatric growth hormone disorders from the European Society for Paediatric Endocrinology (ESPE) Congress in Vienna, Austria, 19–21 September 2019.

The potential implications of these data for improving the care of paediatric patients with growth hormone disorders are explored with a focus on advances in understanding the biology, diagnosis and treatment of severe primary IGF-1 deficiency, growth hormone deficiency and other disorders of growth.

The information in this activity is intended for European endocrinologists and other healthcare professionals involved in the treatment of paediatric patients with growth disorders.

Learning Objectives

After watching these touchCONGRESS Expert Interviews, you should be able to:

Recall the latest advances in understanding the biology of paediatric growth disorders
Interpret the latest data for the diagnosis and management of paediatric growth disorders and their impact on daily clinical practice
Recognize the importance of personalized medicine on clinical outcomes

PROF. MARTIN SAVAGE

Watch in English

Martin Savage, Professor Emeritus at the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK, discusses what the latest data presented at ESPE 2019 might mean in clinical practice for the diagnosis, treatment and management of children with growth disorders.

Clinical Spotlight

New genetic techniques are identifying non-classical, less severe forms of growth hormone insensitivity (GHI). Will this finding change your clinical practice in any way?
The EU-IGFD registry revealed huge variations in SPIGFD treatment practices across the EU. What are your thoughts on this and do you feel there is a need for international collaboration to determine best practice?
Studies presented at ESPE 2019 indicates a future where patients with growth hormone deficiency (GHD) will have the option of once-weekly rather than once-daily recombinant human growth hormone. What are the implications for clinical practice and patient outcomes?
A study presented at ESPE 2019 showed moderate agreement between self-report and objective compliance among children with GHD. Will this finding change your clinical practice in any way?
A review of current clinical and genetic information for growth disorders is facilitating the development of new taxonomic classifications. How would a taxonomic classification impact your clinical practice?

About PROF. MARTIN SAVAGE

Prof. Savage, MA, MD, FRCP, FRCPCH, is Professor Emeritus at the William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University, London, UK. Between 1982 and 2007 he was also Head of the Paediatric Endocrine Unit at both Universities. Since January 2008, he has worked for the London Clinic Centre for Endocrinology as a self-employed Consultant Professor of Paediatric Endocrinology.

Prof. Savage has extensive clinical and research experience, with his main research interests being within the field of growth disorders, particularly those involving defects in the growth hormone IGF-1 axis. Much of his research has been focused on looking at the genotype-phenotype relationship of such defects.

Prof. Savage held the role of General Secretary of the European Society for Paediatric Endocrinology from 1997 to 2004. He has published over 570 research articles, reviews and book chapters and has lectured internationally at more than 50 different institutions. Prof. Savage was awarded the ESPE Andrea Prader prize in 2007 for his contributions to Paediatric Endocrinology.

Disclosures: Consultancy agreements with Genexine/Handok, Global, Merck KGaA Darmstadt, Novartis, OPKO, Sandoz UK and Springer IME. Speaker honoraria from prof. Novo Nordisk and Pfizer.